Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Compass Pathways’ Phase 3 COMP360 study readout lays down its first marker.</li><li>Compass Pathways’ (NASDAQ:CMPS) much anticipated top-line Part A readout of its COMP005 pivotal two-arm trial for its lead psilocybin-based monotherapy candidate for treatment-resistant depression (TRD), COMP360, has produced a statistically significant (p-value of &lt;0.001) and clinically meaningful -3.6 mean difference in the MADRS scale comparing a one-time administered 25mg dose of COMP360 with placebo at six weeks in a 258-participant study.</li><li>Based on a statement from the independent Data and Safety Monitoring Board (DSMB), the Part A study resulted in no new or unexpected safety findings.</li></ul>

Compass Pathways’ Phase 3 COMP360 study readout lays down its first marker.Compass Pathways’ (NASDAQ:CMPS) much anticipated top-line Part A readout of its COMP005 pivotal two-arm trial for its lead psilocybin-based monotherapy candidate for treatment-resistant depression (TRD), COMP360, has produced a statistically significant (p-value of &lt;0.001) and clinically meaningful -3.6 mean difference in the MADRS scale comparing a one-time administered 25mg dose of COMP360 with placebo at six weeks in a 258-participant study.Based on a statement from the independent Data and Safety Monitoring Board (DSMB), the Part A study resulted in no new or unexpected safety findings.

Cybin, Inc.：うつ病に対するサイケデリック治療はどれも同じではない